Back to search

Democritus University of Thrace (DUTH)

Μελέτη της δράσης της αντι-ανδρογονικής θεραπείας στο μεταβολισμό, την αυτοφαγία και την ευαισθησία των καρκινικών κυττάρων του προστάτη στην ακτινοθεραπεία και χημειοθεραπεία

Abstract

dc:description

The objective of the present study is to provide data about the in vitro efficacy of three anti-androgens (ARN-509/Apalutamide, Bicalutamide and Enzalutamide) to block the Androgen Receptor (AR) pathway and the induction of downstream genes, as well as their effect on PC cells proliferation. We also aim to study and compare the radio-sensitizing effect of three anti-androgens and the molecular pathways induced by this interaction. Two androgen- independent cell lines DU145, PC3 and the androgen- dependent 22Rv1 cell line were used for this study. At first, we tested the effect of testosterone, under the presence or absence of anti-androgens, on the proliferation of the three prostate cancer cell lines. Next, we identified changes induced by testosterone (with or w/o anti-androgens) on the cytoplasmic/nuclear kinetics of the AR and on the expression of AR down-stream proteins (PSA, TMPRSS2). We also studied the effects of testosterone and anti-androgens on the expression of proteins involved in tumour hypoxia, in anerobic metabolism and in autophagy. For the second stage, we investigate the radiation sensitivity of the three prostate cancer cells under exposure to Apalutamide, or Bicalutamide or Enzalutamide, in comparison to radiation alone. Furthermore, we investigated the death pathway induced by androgens in combination with RT. Finally, we used two NOD SCID (NOD.CB17-Prkdcscid/J, Genotype: HOM Homozygous for Prkdcscid) and R2G2 (B6.129-Rag2 tm1Fwa II2rg tm1Rsky /DwlHsd) and the 22Rv1 cell line, in order to study the radio-sensitizing effect of Apalutamide and Bicalutamide, in vivo. The hormone-responsive PC cell line, 22Rv1, showed an increase in proliferation and a strong response of AR and AR-V7 kinetics to testosterone. PSA and TMPRSS2 were also induced by testosterone in the 22Rv1 cells but not in the DU145 and PC3 cells. In addition, apalutamide had the most potent inhibitory effect on the testosterone-induced expression of AR and downstream genes in the 22Rv1 cells. Testosterone and anti-androgens did not change the expression levels of proteins related to hypoxia. Similarly, no changes were observed in the glucose metabolism pathway nor in the autophagy pathway. All three anti-androgens suppressed the proliferation/viability of all three PC cell lines at similar concentrations (10-50μM). Interestingly, Apalutamide and Enzalutamide at higher doses (100μΜ) resulted in the complete inhibition of proliferation in 22Rv1 hormone-sensitive cells and in a significant proliferation reduction in the PC3 and DU145 cells. The results of the radiation experiments showed that Enzalutamide and Apalutamide have a strong dose-dependent radiosensitivity effect in all three PC cell lines. An interesting finding was observed in all three cell lines when RT was combined with Apalutamide or Enzalutamide, albeit at a far lesser degree. At 30 minutes and 4h post RT confocal microscopy showed intense γΗ2ΑΧ foci localization in large round structures that indicated a specific death pattern that includes nuclear fragmentation. This type of cell death it is not apoptosis and does not occur when cells were treated with RT alone or RT combined with Bicalutamide.The in vivo experiments showed that both Apalutamide and Bicalutamide exhibited a significant radio-sensitizing effect, reducing the growth rate of xenografts compared to xenografts treated with radiation only. Apalutamide showed a significant stronger effect compared to Bicalutamide. Also, tumors treated with the combination of radiation and Apalutamide showed a significantly higher percentage of necrosis compared with tumors treated with radiation only or with radiation in combination with Bicalutamide. Finally, the chemo-sensitizing experiments showed that all three anti-androgens enhanced the cytotoxic effect of cabazitaxel in 22Rv1 cells, while only Apalutamide and Enzalutamide had the same effect in PC3 cells. On the other hand, none of anti-androgens showed any effect with cabazitaxel in DU145 cells. Apalutamide was the only anti-androgen that enhanced the cytotoxic effect of docetaxel and only in 22Rv1 cells. Overall, we showed that second generation anti-androgens (and especially Apalutamide) have a more potent effect on blocking the AR pathway and the testosterone- induced expression of downstream proteins such as PSA and TMPRSS2 than bicalutamide. Second-generation anti-androgens were also superior in suppressing prostate cancer cell proliferation. Moreover, we proved that second generation antiandrogens demonstrate a strong radio- sensitizing effect against prostate cancer cells regardless of hormone-dependency. That radio- sensitizing effect of Apalutamide is far stronger than the effect produced by bicalutamide. In vivo experiments confirmed the above findings. Our results can serve as a solid basis for subsequent clinical trials on the concurrent use of second generation anti-androgens (Apalutamide or Enzalutamide) in conjunction with Radiotherapy.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2021

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kakouratos, Christos
  • Κακουράτος, Χρήστος

Subjects

dc:subject × 12

Rights

dc:rights
Statement dc:rights
  • BY_NC
Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/49067

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kakouratos, Christos; Κακουράτος, Χρήστος. Μελέτη της δράσης της αντι-ανδρογονικής θεραπείας στο μεταβολισμό, την αυτοφαγία και την ευαισθησία των καρκινικών κυττάρων του προστάτη στην ακτινοθεραπεία και χημειοθεραπεία. Democritus University of Thrace (DUTH), 2021. http://hdl.handle.net/10442/hedi/49067